Built for Life Science Startups. Backed by Experts.
Science Inc. | Life Sciences is a 14-week accelerator helping founders de-risk, connect, and grow.
Applications for Fall 2025 are now closed.
About the Science Inc.™ | Life Sciences Accelerator
Science Inc. | Life Sciences is designed for early-stage startups advancing complex life science technologies. Each cohort provides deep commercialization support, expert mentorship, and high-impact connections.
Our Fall 2025 cohort is dedicated to Life Sciences startups developing:
- Novel therapeutics
- Platform biotechnologies
- Drug delivery systems
- Enabling tools in cell and gene therapy, synthetic biology, or biomanufacturing
What You’ll Gain
Sector-Specific Curriculum
The 14-week hybrid program focuses on critical areas for founders in biotech and therapeutic innovation:
- Key milestones and value inflection points
- Clinical and regulatory strategy
- Data room elements
- Investor outreach and engagement
Expert Mentorship & Strategic Support
You’ll be connected to seasoned industry leaders, investors, and technical advisors who understand the regulatory, scientific, and business dynamics of life science innovation.
Resources & Community Access
Founders can tap into The Innovation Space’s community of experts, as well as exclusive perks like PitchBook access, onsite coworking, founder events, and targeted partner introductions.
Visibility & Investor Connections
Demo Day and curated pitch opportunities help you tell your story, gain exposure, and build relationships with investors and stakeholders focused on early-stage life sciences.
Program Snapshot
- Timeline: September–December 2025
- Format: Hybrid (virtual delivery + 2 Required In-Person Events)
- Location: Virtual + Wilmington, DE
- Application Deadline: July 8, 2025
Key In-Person Events
- October 9: Live Pitch Workshop
- December 11–12: Final Pitch Event & Science Inc. Days Celebration
Applications for Fall 2025 are now closed.
Who Should Apply
We’re looking for founders advancing transformative solutions in therapeutics, biotechnology, or drug delivery with the following in place:
- A defined scientific innovation with early validation
- Completed foundational market research
- A business model and milestone roadmap
- At least $50,000 raised (dilutive or non-dilutive)
- A plan to fundraise within the next 12 months
Preference will be given to companies based in or expanding to the Mid-Atlantic region.
What Founders Are Saying
“Science Inc. was a great platform to build our network beyond our local ecosystem. The advisors had real, meaningful experience in building life science businesses from the ground up.”
— Spencer Matonis, CEO, Edulis Therapeutics